Skip to main content

Table 4 Crude and adjusted hazard ratios for the association between a variable and the risk of NTM infection within the 1st year after the diagnosis

From: The risk of nontuberculous mycobacterial infection in patients with Sjögren’s syndrome: a nationwide, population-based cohort study

 

Univariate analysis

Model A

Model B

 

HR

(95%CI)

HR

(95%CI)

HR

(95%CI)

Group

 Non- SS

Reference

Reference

Reference

Reference

Reference

Reference

 SS

16.06

(3.24–79.60)

5.22

(0.71–38.64)

  

  SS treated without immunosuppressants

6.28

(0.65–60.42)

  

4.04

(0.39–41.85)

  SS treated with immunosuppressants

72.39

(12.09–433.31)

  

33.33

(4.37–254.23)

Age

  < 50 years

Reference

Reference

Reference

Reference

Reference

Reference

  ≥ 50 years

2.66

(0.31–22.76)

1.60

(0.17–15.09)

1.61

(0.17–15.25)

Gender

 Female

Reference

Reference

Reference

Reference

Reference

Reference

 Male

3.81

(0.70–20.79)

2.92

(0.53–16.19)

2.85

(0.51–15.80)

CCI group

 0

Reference

Reference

Reference

Reference

Reference

Reference

  ≥ 1

6.89

(1.26–37.61)

4.05

(0.67–24.28)

4.16

(0.69–24.98)

Medications

 Immunosuppressants

39.16

(7.17–213.81)

6.21

(0.75–51.40)

  

 Steroid

6.94

(1.27–37.90)

2.55

(0.37–17.46)

2.65

(0.38–18.24)

  1. Immunosuppressants: methotrexate, cyclophosphamide, or azathioprine. Abbreviations: SS Sjögren’s Syndrome, CCI Charlson comorbidity index